deltatrials
Recruiting PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT04643002

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol

Sponsor: Sanofi

Conditions Plasma Cell Myeloma Refractory
Interventions Belantamab mafodotin Belumosudil Dexamethasone Evorpacept Isatuximab Pegenzileukin Pomalidomide SAR439459
Updated 30 times since 2020 Last updated: Aug 8, 2025 Started: Jan 25, 2021 Primary completion: Sep 13, 2027 Completion: Apr 20, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Plasma Cell Myeloma Refractory, this trial is actively recruiting participants. The trial is conducted by Sanofi and has accumulated 30 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Jun 2023 · 2 months · monthly snapshot~Jun 2023 – ~Sep 2023 · 3 months · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Jan 2024 · 3 months · monthly snapshot~Jan 2024 – ~Jun 2024 · 5 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Mar 2025 · 5 months · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~Jun 2025 · 2 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

30 versions recorded

  1. Sep 2025 — Present [monthly]

    Recruiting PHASE1/PHASE2

  2. Jun 2025 — Sep 2025 [monthly]

    Recruiting PHASE1/PHASE2

  3. Apr 2025 — Jun 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Mar 2025 — Apr 2025 [monthly]

    Recruiting PHASE1/PHASE2

  5. Oct 2024 — Mar 2025 [monthly]

    Recruiting PHASE1/PHASE2

▶ Show 25 earlier versions

  1. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1/PHASE2

  2. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

  3. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jan 2024 — Jun 2024 [monthly]

    Recruiting PHASE1_PHASE2

  6. Oct 2023 — Jan 2024 [monthly]

    Recruiting PHASE1_PHASE2

  7. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jun 2023 — Sep 2023 [monthly]

    Recruiting PHASE1_PHASE2

  9. Apr 2023 — Jun 2023 [monthly]

    Recruiting PHASE1_PHASE2

  10. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE1_PHASE2

  11. Nov 2022 — Feb 2023 [monthly]

    Recruiting PHASE1_PHASE2

  12. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  14. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE1_PHASE2

  15. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE1_PHASE2

  16. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE1_PHASE2

  17. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE1_PHASE2

  18. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE1_PHASE2

  19. Dec 2021 — Feb 2022 [monthly]

    Recruiting PHASE1_PHASE2

  20. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE1_PHASE2

  21. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  22. Mar 2021 — May 2021 [monthly]

    Recruiting PHASE1_PHASE2

  23. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  24. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  25. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sanofi
Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Athens, Greece , Atlanta, United States , Buffalo, United States , Chicago, United States , Coimbra, Portugal , Frankfurt, Germany , HATO REY, Puerto Rico , Jerusalem, Israel , Lille, France and 12 more locations